Atul Deodhar
Overview
Explore the profile of Atul Deodhar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
246
Citations
5698
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mease P, Korotaeva T, Shesternya P, Kokhan M, Rukavitsyn A, Vasilchenkov D, et al.
Rheumatol Ther
. 2024 Sep;
11(6):1551-1567.
PMID: 39320583
Introduction: There are limited data on the use of advanced therapies to treat psoriatic arthritis (PsA) in Russia. Guselkumab, an interleukin (IL)-23p19-subunit inhibitor, demonstrated efficacy in patients with PsA in...
12.
Deodhar A, Supronik J, Kivitz A, Valenzuela G, Kapur K, Rohrer S, et al.
Arthritis Rheumatol
. 2024 Sep;
77(2):163-170.
PMID: 39300513
Objective: Our goal was to assess the efficacy and safety of intravenous (IV) secukinumab for the treatment of adults with active axial spondyloarthritis (axSpA) in INVIGORATE-1. Methods: INVIGORATE-1 (NCT04156620) was...
13.
Curtis J, Deodhar A, Soriano E, Rampakakis E, Shawi M, Shiff N, et al.
Rheumatol Ther
. 2024 Sep;
11(6):1501-1517.
PMID: 39261446
Introduction: Patterns of treatment response can inform clinical decision-making. This study assessed the course and impact of achieving minimal clinically important improvement (MCII) in clinical measures and patient-reported outcomes (PROs)...
14.
Deodhar A, Kivitz A, Magrey M, Walsh J, Mease P, Greenwald M, et al.
Rheumatology (Oxford)
. 2024 Aug;
PMID: 39133200
Objective: To investigate the clinical response at week 52 in patients with ankylosing spondylitis (AS) who received secukinumab 300 vs 150 mg after inadequate response to 150 mg at week...
15.
Stolnicki D, Coates L, Gollins C, Koppikar S, Perez-Chada L, Puig L, et al.
J Rheumatol
. 2024 Aug;
51(Suppl 2):54-57.
PMID: 39089830
Multidisciplinary care is essential for the management of patients with psoriatic disease (PsD), considering the great range of cutaneous and musculoskeletal symptoms and the potential for associated comorbidities and extraarticular...
16.
Elliott A, Gill T, Kim J, Shutova M, FitzGerald O, Pennington S, et al.
J Rheumatol
. 2024 Jul;
51(Suppl 2):96-100.
PMID: 39009398
Research progress from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) pilot award program was presented and discussed at the GRAPPA 2023 annual meeting. Topics included...
17.
Brown M, Rudwaleit M, van Gaalen F, Haroon N, Gensler L, Fleurinck C, et al.
Ann Rheum Dis
. 2024 Jul;
83(12):1722-1730.
PMID: 38977276
Objectives: Acute anterior uveitis ('uveitis') is a common axial spondyloarthritis (axSpA) extramusculoskeletal manifestation. Interleukin (IL)-17 is implicated in its pathogenesis, however, there is conflicting evidence for IL-17A inhibition in uveitis...
18.
Ritchlin C, Mease P, Boehncke W, Tesser J, Chakravarty S, Rampakakis E, et al.
Clin Rheumatol
. 2024 Jun;
43(8):2551-2563.
PMID: 38844682
Objectives: Evaluate patterns of stringent disease control with 2 years of guselkumab across key disease-identified domains and patient-reported outcomes (PROs) in subgroups of patients with psoriatic arthritis (PsA) defined by...
19.
Dubreuil M, Navarro-Compan V, Boonen A, Gaffney K, Gensler L, de la Loge C, et al.
RMD Open
. 2024 Jun;
10(2).
PMID: 38834351
Objective: To assess the impact of bimekizumab on physical functioning, sleep, work productivity and overall health-related quality of life (HRQoL) in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis...
20.
Deodhar A, Baraliakos X, Magrey M, Gensler L, Thorat A, Pemmaraju S, et al.
J Rheumatol
. 2024 Jun;
51(8):772-780.
PMID: 38825359
Objective: This post hoc analysis assessed the effect of baseline C-reactive protein (CRP) on the efficacy and safety of tofacitinib (TOF) use in ankylosing spondylitis (AS), as well as patient-reported...